The Benchmark Company, LLC
150 East 58th Street, 17th Floor
New York, New York 10155
February 3, 2020
VIA FACSIMILE AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, D.C. 20549
Re: SEELOS THERAPEUTICS, INC.
Registration Statement on Form S-1 (Registration No. 333-236002)
Concurrence in Acceleration Request
Ladies and Gentlemen:
The Benchmark Company, LLC ("Benchmark"), as representative of the underwriters for the referenced offering, hereby concurs in the request by Seelos Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on February 5, 2020, pursuant to Rule 461 under the Securities Act. Benchmark affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
THE BENCHMARK COMPANY, LLC
By: /s/ Brad Carlsson
Name: Brad Carlsson
Title: Managing Director, Investment Banking
